New drug combo aims to extend relief for ITP patients

NCT ID NCT05653219

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 25 times

Summary

This study tests whether adding ianalumab to the standard drug eltrombopag can help adults with primary immune thrombocytopenia (ITP) who did not get better or relapsed after steroid treatment. ITP is a condition where the immune system destroys platelets, causing bleeding risks. The trial involves 152 participants and measures how long the treatment keeps platelet counts stable without needing additional therapies. The goal is to improve disease control, not to cure the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Boston Medical Center

Boston, Massachusetts, 02118, United States
Hematology Oncology Association of Rockland

Nyack, New York, 10960, United States
Michigan Center of Medical Research

Farmington Hills, Michigan, 48334, United States
Montefiore Medical Center

The Bronx, New York, 10461, United States
NorthShore University Health System

Evanston, Illinois, 60201, United States
Novartis Investigative Site

CABA, C1181ACH, Argentina
Novartis Investigative Site

Vienna, A 1090, Austria
Novartis Investigative Site

Yvoir, Namur, 5530, Belgium
Novartis Investigative Site

Roeselare, West-Vlaanderen, 8800, Belgium
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Wuhan, Hubei, 430022, China
Novartis Investigative Site

Binzhou, Shandong, 256603, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site

Beijing, 100730, China
Novartis Investigative Site

Jinan, 250012, China
Novartis Investigative Site

Tianjin, 300020, China
Novartis Investigative Site

Brno, 625 00, Czechia
Novartis Investigative Site

Prague, 100 34, Czechia
Novartis Investigative Site

Prague, 128 08, Czechia
Novartis Investigative Site

Blois, 41000, France
Novartis Investigative Site

Le Mans, 72000, France
Novartis Investigative Site

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site

Düsseldorf, North Rhine-Westphalia, 40225, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Aachen, 52074, Germany
Novartis Investigative Site

Bonn, 53105, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site

Budapest, H-1083, Hungary
Novartis Investigative Site

Rishikesh, Uttarakhand, 249203, India
Novartis Investigative Site

Kolkata, West Bengal, 700014, India
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Roma, RM, 00133, Italy
Novartis Investigative Site

Roma, RM, 00168, Italy
Novartis Investigative Site

Trieste, TS, 34129, Italy
Novartis Investigative Site

Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site

Osaka, Osaka, 5400006, Japan
Novartis Investigative Site

Suita, Osaka, 565-0871, Japan
Novartis Investigative Site

Kofu, Yamanashi, 400-8506, Japan
Novartis Investigative Site

Kumamoto, 860-0008, Japan
Novartis Investigative Site

George Town, Pulau Pinang, 10450, Malaysia
Novartis Investigative Site

Kota Kinabalu, Sabah, 88586, Malaysia
Novartis Investigative Site

Subang Jaya, Selangor, 47500, Malaysia
Novartis Investigative Site

George Town, 10050, Malaysia
Novartis Investigative Site

Johor Bahru, 80100, Malaysia
Novartis Investigative Site

Kuala Selangor, 68000, Malaysia
Novartis Investigative Site

Saltillo, Coahuila, 25230, Mexico
Novartis Investigative Site

Morelia, Michoacán, 58260, Mexico
Novartis Investigative Site

Monterrey, Nuevo León, 64460, Mexico
Novartis Investigative Site

Leiden, South Holland, 2333 ZA, Netherlands
Novartis Investigative Site

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site

Makati City, 1229, Philippines
Novartis Investigative Site

Quezon, 1102, Philippines
Novartis Investigative Site

Craiova, Dolj, 200136, Romania
Novartis Investigative Site

Timișoara, 300079, Romania
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 169608, Singapore
Novartis Investigative Site

Jeollanam, 519763, South Korea
Novartis Investigative Site

Seoul, 06591, South Korea
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Taoyuan, 33305, Taiwan
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Novartis Investigative Site

Samsun, Atakum, 55200, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Bilkent Cankaya, 06800, Turkey (Türkiye)
Novartis Investigative Site

Aydin, Efeler, 09100, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site

Izmir, 35100, Turkey (Türkiye)
Novartis Investigative Site

London, E1 1BB, United Kingdom
Novartis Investigative Site

London, W12 0HS, United Kingdom
Novartis Investigative Site

Oxford, OX3 7LE, United Kingdom
St Vincent Frontier Cancer Center

Billings, Montana, 59102, United States
UMASS Memorial Medical Center

Worcester, Massachusetts, 01665, United States
University of Colorado Anschutz

Aurora, Colorado, 80045, United States
Yuma Regional Medical Center

Yuma, Arizona, 85349, United States

Conditions

Explore the condition pages connected to this study.

PRIMARY IMMUNE THROMBOCYTOPENIA